Veterinärmedizinische Universität Wien Forschungsinformationssystem VetDoc

Grafischer Link zur Startseite der Vetmeduni Vienna

Exploring and exploiting cellular heterogeneity and epigenetic regulation for the interception of myeloid diseases

Diseases of the blood affecting the myeloid lineage are on the rise in the aging European population. Acute myeloid leukaemia (AML) is one of the most common and devastating cancers and myelodysplastic syndrome (MDS) is the most common hematopoietic disorder of the elderly. Taken MDS and AML together, the economic burden for the European Health system surpasses 3.000 million Euros per year. Despite advances with intensive chemotherapy and allogeneic hematopoietic stem cell transplantation, the development of novel tools for a better management of these disorders and improved quality of patients’ lives is an unmet and urgent need. The regulated packaging of the genome into chromatin represents the basis of epigenetic regulation. Alterations at the level of epigenetics contribute to AML and MDS development and progression. EPIGRAM includes beneficiaries that have previously demonstrated the proof-of-concept that epigenetic regulation can be used for improving prognosis, diagnosis as well as therapy. The EPIGRAM Innovative Training Network will address the health challenge imposed by myeloid malignancies by training the next generation of European leaders. Specifically, EPIGRAM will bring together leaders from three different but highly complementary environments that are basic research, industry and clinical research. Together they will jointly train 12 early stage researchers (ESRs) through co- supervised research and a three-level training programme including training of key transferable skills. EPIGRAM will enable its ESRs to leverage insight in chromatin regulation for the development of tools for improved disease management, transferable to other diseases. Through its highly interactive and open collaborative approach EPIGRAM will help the European Community to promote healthy aging by providing human capital, establish durable links between leading organizations and cross-fertilization between sectors.
Koordination an der Vetmeduni Vienna
Grebien Florian
Koordination Gesamtprojekt
Fundacio Institut de Recerca Contra la Leucemia Josep Carreras, Muntaner 383, 3r 2a, 08021 Barcelona, Spanien
Horizon 2020 - Excellent Science - Marie S. Curie (MSCA) - Innovative Training Networks (ITN) H2020
Art der Forschung
Grebien F.,
Beteiligte Vetmed-Organisationseinheiten
Institut für Medizinische Biochemie
(Weitere) Projektpartner
BioBam Bioinformatics S.L., Avenida Peris y Valero 87-19, 46006 Valencia, Spanien
Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus, Paul-Ehrlich-Straße 42-44, 60596 Frankfurt, Deutschland
Erasmus MC, Dr. Molewaterplein 40, 3015 Rotterdam, Niederlande
Institut National de la Sante et de la Recherche Medicale (INSERM), 101 rue de Tolbiac, 75654 Paris, Frankreich
MLL Münchner Leukämielabor GmbH, Max-Lebsche-Platz 31, 81377 München, Deutschland
Technische Universität München, Arcisstr. 21, 80333 München, Deutschland
Università degli Studi di Firenze, Piazza di San Marco, 4, 50121 Florenz, Italien
Universitetet i Bergen, Museplassen 1, 5020 Bergen, Norwegen
Gefördert durch
EU (Kommission der Europäischen Union), Brussels, Europäische Union
© Veterinärmedizinische Universität Wien Hilfe und DownloadsErklärung zur Barrierefreiheit